InsiderTrades.com logo
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
The AI boom is just getting started. And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.
Paolo Tombesi net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Paolo Tombesi Biography and Net Worth

CFO of Turning Point Therapeutics

Paolo Tombesi serves as executive vice president and chief financial officer. Mr. Tombesi has more than 30 years of global financial and accounting experience within biotech and pharmaceutical companies.

Prior to joining Turning Point Therapeutics, Mr. Tombesi was the chief financial officer of Epizyme, Inc., where he supported the commercial launch of Tazverik (tazemetostat) for the treatment of relapsed or refractory follicular lymphoma, and was responsible for capital funding, treasury, tax and accounting. Prior to Epizyme, he was CFO for Insmed, Inc., where he led financial operations and preparation for the commercial launch of Arikayce (amikacin liposome inhalation suspension). From 2006 to 2014, he served in roles of increasing responsibility for Novartis, including chief financial and administrative officer of Novartis Pharmaceuticals Corporation; managing director and CFO of Novartis Japan; and CFO of the European Oncology division. Earlier in his career, he served in financial roles for Bristol Myers Squibb in the U.S. and Europe, and Unilever and Johnson & Johnson in Italy.

What is Paolo Tombesi's net worth?

The estimated net worth of Paolo Tombesi is at least $2.18 million as of July 27th, 2022. Mr. Tombesi owns 28,700 shares of Turning Point Therapeutics stock worth more than $2,181,487 as of November 25th. This net worth approximation does not reflect any other assets that Mr. Tombesi may own. Additionally, Mr. Tombesi receives a salary of $741,190.00 as CFO at Turning Point Therapeutics. Learn More about Paolo Tombesi's net worth.

How old is Paolo Tombesi?

Mr. Tombesi is currently 58 years old. There are 4 older executives and no younger executives at Turning Point Therapeutics. Learn More on Paolo Tombesi's age.

What is Paolo Tombesi's salary?

As the CFO of Turning Point Therapeutics, Inc., Mr. Tombesi earns $741,190.00 per year. There are 2 executives that earn more than Mr. Tombesi. The highest earning executive at Turning Point Therapeutics is Dr. Athena Maria Countouriotis M.D., Pres, CEO & Director, who commands a salary of $1,190,000.00 per year. Learn More on Paolo Tombesi's salary.

How do I contact Paolo Tombesi?

The corporate mailing address for Mr. Tombesi and other Turning Point Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Turning Point Therapeutics can also be reached via phone at (858) 926-5251 and via email at [email protected]. Learn More on Paolo Tombesi's contact information.

Has Paolo Tombesi been buying or selling shares of Turning Point Therapeutics?

Paolo Tombesi has not been actively trading shares of Turning Point Therapeutics in the last ninety days. Most recently, Paolo Tombesi sold 1,183 shares of the business's stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a transaction totalling $88,654.02. Following the completion of the sale, the chief financial officer now directly owns 28,700 shares of the company's stock, valued at $2,150,778. Learn More on Paolo Tombesi's trading history.

Who are Turning Point Therapeutics' active insiders?

Turning Point Therapeutics' insider roster includes Mark Alles (Director), Brian Baker (SVP), Athena Countouriotis (CEO), Jingrong Cui (Director), Mohammad Hirmand (EVP), Annette North (EVP), Andrew Partridge (EVP), Siegfried Reich (EVP), and Paolo Tombesi (CFO). Learn More on Turning Point Therapeutics' active insiders.

Paolo Tombesi Insider Trading History at Turning Point Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2022Sell1,183$74.94$88,654.0228,700View SEC Filing Icon  
See Full Table

Paolo Tombesi Buying and Selling Activity at Turning Point Therapeutics

This chart shows Paolo Tombesi's buying and selling at Turning Point Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Turning Point Therapeutics Company Overview

Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $76.01
Low: $76.01
High: $76.01

50 Day Range

MA: $75.83
Low: $74.80
High: $76.01

2 Week Range

Now: $76.01
Low: $23.77
High: $82.20

Volume

4,322 shs

Average Volume

1,137,726 shs

Market Capitalization

$3.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Trump won. Buy this coin now.
From Weiss Ratings   |   Ad
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
This could be his favorite coin.